Molecular mechanisms responsible for the differential effects of ApoE3 and ApoE4 on plasma lipoprotein-cholesterol levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 4, 2013, Pages 687-693

  Li, Hui ^a   Dhanasekaran, Padmaja ^a   Alexander, Eric T ^a   Rader, Daniel J ^a   Phillips, Michael C ^a   Lund Katz, Sissel ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

apolipoprotein E; atherosclerosis; cholesterol; high density lipoprotein; very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADENO ASSOCIATED VIRUS; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE DELETION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

AMINO ACID SUBSTITUTION; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOLYSIS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; TRIGLYCERIDES;

EID: 84875367891     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.301193     Document Type: Article

References (35)

1. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res. 2009;suppl 50:S156-S161.
2. Lund-Katz S, Phillips MC. High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem. 2010;51:183-227.
3. Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res. 2011;50:62-74.
4. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;suppl 50:S183-S188.
5. Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 1999;40:1933-1949.
6. Fielding CJ, Fielding PE. Dynamics of lipoprotein transport in the circulatory system. In: Vance DE, Vance JE, eds. Biochemistry of Lipids, Lipoproteins and Membranes. Amsterdam, The Netherlands: Elsevier; 2008.
7. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteinearginine interchange at a single site. J Biol Chem. 1982;257:2518-2521.
8. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
9. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990;31:1503-1511.
10. Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, Lund-Katz S. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Biochemistry. 2010;49:10881-10889.
11. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem. 1994;45:249-302.
12. Saito H, Lund-Katz S, Phillips MC. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res. 2004;43:350-380.
13. Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA. 2011;108:14813-14818.
14. Nguyen D, Dhanasekaran P, Phillips MC, Lund-Katz S. Molecular mechanism of apolipoprotein E binding to lipoprotein particles. Biochemistry. 2009;48:3025-3032.
15. Mizuguchi C, Hata M, Dhanasekaran P, Nickel M, Phillips MC, Lund-Katz S, Saito H. Fluorescence analysis of the lipid binding-induced conformational change of apolipoprotein E4. Biochemistry. 2012;51:5580-5588.
16. Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, Weisgraber KH. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry. 2000;39:11657-11666.
17. Morrow JA, Hatters DM, Lu B, Hocht P, Oberg KA, Rupp B, Weisgraber KH. Apolipoprotein E4 forms a molten globule. J.Biol.Chem. 2002;277: 50380-50385.
18. Sakamoto T, Tanaka M, Vedhachalam C, Nickel M, Nguyen D, Dhanasekaran P, Phillips MC, Lund-Katz S, Saito H. Contributions of the carboxyl-terminal helical segment to the self-association and lipoprotein preferences of human apolipoprotein E3 and E4 isoforms. Biochemistry. 2008;47:2968-2977.
19. Kitajima K, Marchadier DH, Miller GC, Gao GP, Wilson JM, Rader DJ. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol. 2006;26:1852-1857.
20. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
21. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
22. Tsukamoto K, Maugeais C, Glick JM, Rader DJ. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J Lipid Res. 2000;41:253-259.
23. Zannis VI, Chroni A, Kypreos KE, Kan HY, Cesar TB, Zanni EE, Kardassis D. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr Opin Lipidol. 2004;15: 151-166.
24. Alexander ET, Vedhachalam C, Sankaranarayanan S, de la Llera-Moya M, Rothblat GH, Rader DJ, Phillips MC. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2011;31:320-327.
25. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579-1586.
26. Kypreos KE, Zannis VI. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res. 2006;47:521-529.
27. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269:22358-22365.
28. Rensen PC, van Berkel TJ. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem. 1996;271:14791-14799.
29. Jong MC, Dahlmans VE, Hofker MH, Havekes LM. Nascent very-lowdensity lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J. 1997;328 (pt 3):745-750.
30. Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein A, Assmann G, Mahley RW. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem. 1998;273:26388-26393.
31. Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA. 1978;75:4519-4523.
32. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptorrelated protein. J Biol Chem. 1990;265:22453-22459.
33. Rader DJ. Gene therapy for atherosclerosis. Int J Clin Lab Res. 1997;27: 35-43.
34. Harris JD, Evans V, Owen JS. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther. 2006;8:275-287.
35. Vedhachalam C, Narayanaswami V, Neto N, Forte TM, Phillips MC, Lund-Katz S, Bielicki JK. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry. 2007;46:2583-2593.